Glioblastoma remains one of oncology's most resistant tumors, with median survival after recurrence measured in months and virtually no immunotherapy approvals to date. New phase 1 data suggest that targeting a second immune checkpoint — LAG-3 — either alone or alongside the established PD-1 pathway, may open a viable immunological door into this famously immune-cold malignancy.
The trial enrolled patients with recurrent glioblastoma and tested relatlimab, an anti-LAG-3 antibody, both as monotherapy and in combination with nivolumab, an anti-PD-1 agent already approved across several tumor types. The phase 1 design prioritized safety characterization, and both regimens demonstrated acceptable tolerability profiles. Crucially, preliminary clinical response signals emerged in a disease setting where even modest activity is clinically meaningful — recurrent glioblastoma responds to almost nothing after first-line treatment fails.
The significance here lies in the mechanistic rationale. LAG-3 is an inhibitory receptor expressed on exhausted T cells, and its co-expression with PD-1 on tumor-infiltrating lymphocytes has been associated with profound immune dysfunction. Prior work in melanoma established that dual LAG-3/PD-1 blockade can overcome resistance seen with PD-1 monotherapy alone. Glioblastoma, however, poses unique challenges: a highly immunosuppressive tumor microenvironment, the blood-brain barrier limiting drug penetration, and low mutational burden reducing neoantigen availability. Whether the response signals observed here translate into meaningful survival benefit awaits randomized controlled data. Phase 1 trials are explicitly not powered for efficacy conclusions, and single-arm designs in glioblastoma are prone to selection bias. Nevertheless, safety clearance in this population is a necessary prerequisite, and any hint of biological activity in recurrent glioblastoma warrants the serious follow-up this work should prompt.